Table 1
| JIA category/treatment allocation | Median drug free survival time | p-value | Hazard ratio |
|---|---|---|---|
| All JIA patients, n=205 | 35 months | ||
| Treatment without (n=123) vs. with methotrexate (n=82) | 16.6 vs. 61.4 months | 0.006 | 0.49 |
| Treatment without (n=183) vs. with corticosteroids (n=22) | 28.4 months vs. $∞ $ | 0.085 | 0.51 |
| Treatment time on ETA <2 (n=95) vs. >2 years (n=110) | 50.9 vs. 18.2 months | 0.068 | 0.62 |
| Disease duration before ETA <2 (n=75) vs. >2 y (n=129) | 34 vs. 39.5 months | Not significant | 1,51 |
| Wallace criteria* fulfilled (n=118) vs. not fulfilled (n=72) | 35.3 vs. 28.5 months | Not significant | 1,31 |
*Proposed criteria for inactive disease (Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4).